PTC Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1998-01-01

Employees: 1K

Market Cap: $2.7B

Website: http://www.ptcbio.com

Introduction: PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Clinical Trials

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

Phase 3

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: Ataluren

First Posted Date: 2015-05-28

Last Posted Date: 2020-04-27

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 246

Registration Number: NCT02456103

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Miller Children's Hospital Long Beach, Long Beach, California, United States
🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States

and more 67 locations

Effects of Rifampin on the Pharmacokinetics of Ataluren

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ataluren
Drug: Rifampin

First Posted Date: 2015-04-06

Last Posted Date: 2017-12-22

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 15

Registration Number: NCT02409004

Locations: 🇨🇦
Inventiv, Quebec, Canada

PTC596 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: PTC596

First Posted Date: 2015-03-31

Last Posted Date: 2017-12-08

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 31

Registration Number: NCT02404480

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 1 locations

Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Active, not recruiting

Conditions: Muscular Dystrophy, Duchenne

First Posted Date: 2015-02-24

Last Posted Date: 2024-11-20

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 316

Registration Number: NCT02369731

Locations: 🇱🇻
Bērnu klīniskā universitātes slimnīca, Riga, Latvia
🇸🇪
Karolinska Institutet, Stockholm, Sweden
🇬🇧
Children Hospital - Children's Neurosciences Leeds TEACHING HOSPITALS NHS Trust, Leeds, United Kingdom

and more 68 locations

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

Phase 2

Completed

Conditions: Leigh Syndrome

Interventions: Drug: EPI-743

First Posted Date: 2015-02-02

Last Posted Date: 2024-10-23

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 30

Registration Number: NCT02352896

Locations: 🇺🇸
Gregory Enns, Stanford University, California, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Akron Children's Hospital, Akron, Ohio, United States

and more 1 locations

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

Phase 1

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Deflazacort

First Posted Date: 2014-11-20

Last Posted Date: 2017-12-08

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 24

Registration Number: NCT02295748

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
University of Rochester, Rochester, New York, United States

and more 1 locations

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Deflazacort and rifampin
Drug: Deflazacort and Clarithromycin

First Posted Date: 2014-11-10

Last Posted Date: 2017-08-18

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 58

Registration Number: NCT02286635

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Deflazacort

First Posted Date: 2014-11-10

Last Posted Date: 2017-08-18

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 16

Registration Number: NCT02286609

Locations: 🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Deflazacort

First Posted Date: 2014-11-10

Last Posted Date: 2017-08-18

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 16

Registration Number: NCT02286622

Locations: 🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy

Phase 1

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Deflazacort

First Posted Date: 2014-09-29

Last Posted Date: 2017-08-18

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 24

Registration Number: NCT02251600

Locations: 🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy